Search - tctmd.com

Displaying 41 - 60 of 306

Sort: Relevancy | Date

News Daily News

Medicaid Patients With Type 2 Diabetes Face Hurdles Getting Cardioprotective Meds

Michael O'Riordan

April 25, 2025

News Conference News ACC 2025

Tight Fluid Restriction Not Needed in Chronic HF Patients: FRESH-UP

Michael O'Riordan

April 01, 2025

News Conference News ACC 2025

Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI

Caitlin E. Cox

March 30, 2025

News Conference News ACC 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Michael O'Riordan

March 29, 2025

News Daily News

REVIVED/STICHES Analysis Questions Surgery’s Benefit in Ischemic HF

Michael O'Riordan

March 11, 2025

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for February 2025

Shelley Wood

February 28, 2025

News Daily News

GLP-1 Drugs in Diabetes Don’t Raise Suicidality Risk, New Data Confirm

Caitlin E. Cox

February 26, 2025

News Daily News

Sotagliflozin Reduces Ischemic Risk in SCORED Analysis

Yael L. Maxwell

February 25, 2025

News Daily News

Aortic Stenosis Slowed by SGLT2 Inhibitors in Observational Study

Yael L. Maxwell

February 20, 2025

News Conference News THT 2025

AIM-POWER: Remote, App-Based Intervention Boosts GDMT Use in HFrEF

Todd Neale

February 13, 2025

Presentation THT 2025

Impact of SGLT2 Inhibitors on Mortality and Cardiovascular Admissions in Heart Failure With Reduced Ejection Fraction (HFrEF)

Presenter: Jonathan Zawadzki

February 12, 2025

Presentation THT Abstracts 2025

Association of SGLT2 Inhibitors With Clinical Outcomes in Patients With Severe Renal Impairment (Estimated Glomerular Filtration Rate < 30) and Heart Failure With Reduced Ejection Fraction (HFrEF)

Presenter: Jonathan Zawadzki

February 11, 2025

Presentation THT Abstracts 2025

Evaluating the Impact of Sglt2 Inhibitors on Outcomes in Patients With Sarcoidosis and Heart Failure With Preserved Ejection Fraction

Presenter: Emmanuel Otabor

February 11, 2025

Presentation THT 2025

Association of SGLT2 Inhibitors With Clinical Outcomes in Patients With Severe Renal Impairment (Estimated Glomerular Filtration Rate < 30) and Heart Failure With Reduced Ejection Fraction (HFrEF)

Presenter: Jonathan Zawadzki

February 11, 2025

Presentation THT 2025

Evaluating the Impact of Sglt2 Inhibitors on Outcomes in Patients With Sarcoidosis and Heart Failure With Preserved Ejection Fraction

Presenter: Emmanuel Otabor

February 11, 2025

News Opinion CV Team Dispatch

January 2025 Dispatch for the CV Team

L.A. McKeown

January 24, 2025

News Daily News

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Michael O'Riordan

January 22, 2025

News Daily News

Change in Kidney Function With Finerenone Doesn’t Impact Treatment’s Benefit

Michael O'Riordan

January 13, 2025

News Opinion CV Team Dispatch

December 2024 Dispatch for the CV Team

L.A. McKeown

December 20, 2024

News Daily News

PREVENT Tool Accurately Predicts HF Risk, With ‘Strong’ ASCVD Overlap

Yael L. Maxwell

December 17, 2024

Advertisement

Medicaid Patients With Type 2 Diabetes Face Hurdles Getting Cardioprotective Meds

Tight Fluid Restriction Not Needed in Chronic HF Patients: FRESH-UP

Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

REVIVED/STICHES Analysis Questions Surgery’s Benefit in Ischemic HF

TCTMD’s Top 10 Most Popular Stories for February 2025

GLP-1 Drugs in Diabetes Don’t Raise Suicidality Risk, New Data Confirm

Sotagliflozin Reduces Ischemic Risk in SCORED Analysis

Aortic Stenosis Slowed by SGLT2 Inhibitors in Observational Study

AIM-POWER: Remote, App-Based Intervention Boosts GDMT Use in HFrEF

Impact of SGLT2 Inhibitors on Mortality and Cardiovascular Admissions in Heart Failure With Reduced Ejection Fraction (HFrEF)

Association of SGLT2 Inhibitors With Clinical Outcomes in Patients With Severe Renal Impairment (Estimated Glomerular Filtration Rate < 30) and Heart Failure With Reduced Ejection Fraction (HFrEF)

Evaluating the Impact of Sglt2 Inhibitors on Outcomes in Patients With Sarcoidosis and Heart Failure With Preserved Ejection Fraction

Association of SGLT2 Inhibitors With Clinical Outcomes in Patients With Severe Renal Impairment (Estimated Glomerular Filtration Rate < 30) and Heart Failure With Reduced Ejection Fraction (HFrEF)

Evaluating the Impact of Sglt2 Inhibitors on Outcomes in Patients With Sarcoidosis and Heart Failure With Preserved Ejection Fraction

January 2025 Dispatch for the CV Team

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Change in Kidney Function With Finerenone Doesn’t Impact Treatment’s Benefit

December 2024 Dispatch for the CV Team

PREVENT Tool Accurately Predicts HF Risk, With ‘Strong’ ASCVD Overlap

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content